Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 19/20 | 0.51 |
| ▸ | PRKCB | P05771 | 14/20 | 0.51 |
| ▸ | PRKCG | P05129 | 6/20 | 0.51 |
| ▸ | PRKCA | P17252 | 6/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.49 |
| ▸ | CDK2 | P24941 | 3/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.49 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | LYN | P07948 | 1/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13211425 | 0.92 | GSK3B (0.41) | GSK3BPRKCBPRKCGPRKCACCNA2 | |
| SCHEMBL2974611 | 0.89 | GSK3B (0.63) | GSK3BPRKCBPRKCGPRKCACCNA2 | |
| SCHEMBL2982826 | 0.88 | GSK3B (0.59) | GSK3BPRKCBPRKCGPRKCACCNA2 | |
| SCHEMBL4341571 | 0.84 | GSK3B (0.70) | GSK3BPRKCBPRKCGPRKCACCNA2 | |
| SCHEMBL1127972 | 0.83 | GSK3B (0.54) | GSK3BPRKCBPRKCGPRKCACCNA2 | |
| SCHEMBL1127715 | 0.82 | GSK3B (0.55) | GSK3BPRKCBPRKCGPRKCACCNA2 | |
| SCHEMBL2974640 | 0.82 | GSK3B (0.57) | GSK3BPRKCBPRKCGPRKCACCNA2 | |
| SCHEMBL13204261 | 0.82 | GSK3B (0.55) | GSK3BPRKCBPRKCGPRKCACCNA2 | |
| SCHEMBL2978724 | 0.81 | GSK3B (0.51) | GSK3BPRKCBPRKCGPRKCACCNA2 | |
| SCHEMBL13204338 | 0.79 | GSK3B (0.44) | GSK3BPRKCBPRKCGPRKCACCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786135-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-08-31 | — | — | US | disclosed |
| US-7786135-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-08-31 | — | — | US | disclosed |
| US-7786135-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-08-31 | — | — | US | disclosed |
| US-7781450-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-24 | — | — | US | disclosed |
| US-7781450-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-24 | — | — | US | disclosed |
| US-7781450-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-24 | — | — | US | disclosed |
| US-7705015-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-04-27 | — | — | US | disclosed |
| US-7705015-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-04-27 | — | — | US | disclosed |
| US-7705015-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-04-27 | — | — | US | disclosed |
| US-20090181982-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | ZHANG HAN-CHENG | 2009-07-16 | — | — | US | disclosed |
| EP-1900738-A2 | Substituted pyrroline kinase inhibitors | Janssen Pharmaceutica, N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1900738-A2 | Substituted pyrroline kinase inhibitors | Janssen Pharmaceutica, N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1506192-B1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-27 | — | — | EP | disclosed |
| EP-1506192-B1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-27 | — | — | EP | disclosed |
| US-7125878-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA (BE) | 2006-10-24 | — | — | US | disclosed |
| US-20060205762-A1 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-14 | — | — | US | disclosed |
| US-20060205763-A1 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-14 | — | — | US | disclosed |
| EP-1506192-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | disclosed |
| US-20040006095-A1 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMAECUTICA, NV (BE) | 2004-01-08 | — | — | US | disclosed |
| WO-2003095452-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205762-A1 | Substituted pyrroline kinase inhibitors | PRKDC, PRKACA, MAP3K20 | GSK3B 1267/4885PRKCB 22/4885PRKCG 66/4885 |
| US-20040006095-A1 | Substituted pyrroline kinase inhibitors | PRKDC, PRKACA, MAP3K20 | GSK3B 1267/4885PRKCB 22/4885PRKCG 66/4885 |
| US-20090181982-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | PRKDC, PRKACA, MAP3K20 | GSK3B 1267/4885PRKCB 22/4885PRKCG 66/4885 |
| US-20060205763-A1 | Substituted pyrroline kinase inhibitors | PRKDC, PRKACA, MAP3K20 | GSK3B 1267/4885PRKCB 22/4885PRKCG 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.